Inspection access is not “an administrative footnote,” leaders of key FDA divisions wrote in an editorial on Wednesday vowing to expand oversight of foreign clinical trial sites.
Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new ...
Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it ...
Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate ...
Almost as many biotechs have opted for a reverse merger to reach the public markets as those executing more traditional ...
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of ...
Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases ...
After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as ...
Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to ...
Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases ...
Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results